Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 5
2003 9
2004 4
2005 5
2006 9
2007 17
2008 5
2009 7
2010 7
2011 7
2012 2
2013 10
2014 15
2015 18
2016 5
2017 7
2018 9
2019 11
2020 12
2021 12
2022 5
2023 12
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Results by year

Filters applied: . Clear all
Page 1
The molecular classification of multiple myeloma.
Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD Jr. Zhan F, et al. Blood. 2006 Sep 15;108(6):2020-8. doi: 10.1182/blood-2005-11-013458. Epub 2006 May 25. Blood. 2006. PMID: 16728703 Free PMC article.
CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation.
Gai D, Chen JR, Stewart JP, Nookaew I, Habelhah H, Ashby C, Sun F, Cheng Y, Li C, Xu H, Peng B, Garg TK, Schinke C, Thanendrarajan S, Zangari M, Chen F, Barlogie B, van Rhee F, Tricot G, Shaughnessy JD Jr, Zhan F. Gai D, et al. Among authors: zhan f. J Clin Invest. 2022 Sep 15;132(18):e159527. doi: 10.1172/JCI159527. J Clin Invest. 2022. PMID: 35881476 Free PMC article.
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth.
Sun F, Cheng Y, Wanchai V, Guo W, Mery D, Xu H, Gai D, Siegel E, Bailey C, Ashby C, Al Hadidi S, Schinke C, Thanendrarajan S, Ma Y, Yi Q, Orlowski RZ, Zangari M, van Rhee F, Janz S, Bishop G, Tricot G, Shaughnessy JD Jr, Zhan F. Sun F, et al. Among authors: zhan f. Nat Commun. 2024 Jan 19;15(1):615. doi: 10.1038/s41467-024-44873-4. Nat Commun. 2024. PMID: 38242888 Free PMC article.
Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma.
Xu L, Wang Y, Wang G, Guo S, Yu D, Feng Q, Hu K, Chen G, Li B, Xu Z, Jia X, Lu Y, Zhang H, Gao X, Chang S, Wang H, Wu X, Song D, Yang G, Zhu H, Zhou J, Zhan F, Zhu W, Shi J. Xu L, et al. Among authors: zhan f. Leukemia. 2023 Jul;37(7):1576-1579. doi: 10.1038/s41375-023-01925-w. Epub 2023 May 8. Leukemia. 2023. PMID: 37157015 No abstract available.
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma.
Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Guo W, Cao H, Zhu Y, Ashby C, Bauer MA, Nookaew I, Siegel ER, Ying J, Chen JR, Gai D, Peng B, Xu H, Bailey C, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, Chesi M, Bergsagel PL, van Rhee F, Janz S, Tricot G, Shaughnessy JD Jr, Zhan F. Cheng Y, et al. Among authors: zhan f. Cell Rep Med. 2023 Oct 17;4(10):101214. doi: 10.1016/j.xcrm.2023.101214. Epub 2023 Oct 3. Cell Rep Med. 2023. PMID: 37794587 Free PMC article.
A gene signature can predict risk of MGUS progressing to multiple myeloma.
Sun F, Cheng Y, Ying J, Mery D, Al Hadidi S, Wanchai V, Siegel ER, Xu H, Gai D, Ashby TC, Bailey C, Chen JR, Schinke C, Thanendrarajan S, Zangari M, Janz S, Barlogie B, Van Rhee F, Tricot G, Shaughnessy JD Jr, Zhan F. Sun F, et al. Among authors: zhan f. J Hematol Oncol. 2023 Jun 29;16(1):70. doi: 10.1186/s13045-023-01472-y. J Hematol Oncol. 2023. PMID: 37386588 Free PMC article.
179 results